Year: 2017

Best Ideas 2017” award to Manel Esteller

Last Monday, November 13th, the ‘Best Ideas 2017’ awards ceremony, organized annually by the Diario Médico newspaper, took place at the National Theater of Catalonia. In this year’s edition, Dr. Manel Esteller, Researcher of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Research Professor and Professor of Genetics of the University of Barcelona received one of …

Best Ideas 2017” award to Manel Esteller Read More »

The ‘Viladecans Against Cancer’ Association Coordinator raises 16.186 euros for stomach cancer research in IDIBELL

During the course of an open ‘paella’ that brought together seven hundred and fifty people in the Cúbic space of Viladecans, the Association Viladecans Against Cancer officially offered a 16,186 euros check to IDIBELL for the investigation of new therapies in the fight against stomach cancer, led by Dr. Núria Sala (IDIBELL-ICO). This amount brings …

The ‘Viladecans Against Cancer’ Association Coordinator raises 16.186 euros for stomach cancer research in IDIBELL Read More »

Researchers prove the effectiveness of a new drug to prevent the onset and the pain of chemotherapy-induced neuropathy

Peripheral neuropathy is a very common side-effect of chemotherapy and may eventually lead to early discontinuation of treatment. Collaboration between research and industry led to the identification and successful testing of a new molecule capable of preventing this neurological complication. This molecule could potentially become the first existing treatment to prevent this frequent adverse effect and improve the quality of life of cancer patients. Article citation

A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer

Researchers from the Hereditary Cancer group of the Oncobell Program of the Bellvitge Biomedical Research Institute (IDIBELL) – Hereditary Cancer Program of the Catalan Institute of Oncology (ICO) have found a new genetic marker that would explain up to 1.4% of those inherited colon cancer cases not related to the mutations currently associated with this …

A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer Read More »

Success of the “H2020 Opportunities” informative session

On September 21st, an “Oportunidades en H2020 SC1 2018-20” workshop was held in the Pau Viladiu hall of Duran i Reynals Hospital. This session was jointly organized by IDIBELL’s Research Support Office and ICO’s Research Management Unit on the occasion of the imminent opening of calls for the Work Program of the H2020 Social Challenge …

Success of the “H2020 Opportunities” informative session Read More »

Scroll to Top